Editor’s pick: Indapta Therapeutics

Editor’s pick: Indapta Therapeutics

Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Indapta Therapeutics is using a subset of natural killer cells found in healthy donors to supercharge monoclonal antibodies to fight cancer and autoimmune disease.

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

24,99 € / 30 days

cancel any time

Subscribe to this journal

Receive 12 print issues and online access

209,00 € per year

only 17,42 € per issue

Buy this article

Purchase on Springer LinkInstant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Log in

Learn about institutional subscriptions

Read our FAQs

Contact customer support

Author information

Authors and Affiliations

Berlin, Germany

Iris Marchal

About this article

Cite this article

Marchal, I. Editor’s pick: Indapta Therapeutics.
Nat Biotechnol (2024). https://doi.org/10.1038/s41587-024-02334-9

Download citation

Published: 22 July 2024

DOI: https://doi.org/10.1038/s41587-024-02334-9

>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Nature.com – https://www.nature.com/articles/s41587-024-02334-9

Exit mobile version